Table 2

Comparison of known risk factors, treatment groups, and clinical outcome of patients with high versus low MRD at day 30

VariablesLow MRD, < 10−3 (%)High MRD, ≥ 10−3 (%)P
Total number 246 38 — 
Risk group   Chi-square, < .001 
    Standard risk 160 (65.0) 14 (36.8)  
    High risk 86 (35.0) 24 (63.2)  
WBC count, × 109/L   Chi-square, .02 
    Lower than 50 000 211 (85.8) 27 (71.1)  
    50 000 or higher 35 (14.2) 11 (28.9)  
Age, y   Chi-square, .007 
    0 to younger than 1 7 (2.9) 4 (10.5)  
    1 to younger than 10 205 (83.3) 24 (63.2)  
    10 or older to younger than 18 34 (13.8) 10 (26.3)  
Sex   Chi-square, .61 
    Male 125 (50.8) 21 (55.3)  
    Female 121 (49.2) 17 (44.7)  
Asparaginase treatment   Chi-square, .04 
    Randomized to E coli 82 (33.3) 5 (13.2)  
    Randomized to Erwinia 64 (26.0) 12 (31.6)  
    Direct assigned E coli 100 (40.7) 21 (55.3)  
Relapse   Log rank, < .001 
    Yes 29 (11.8) 27 (71.0)  
    No 217 (88.2) 11 (29.0)  
VariablesLow MRD, < 10−3 (%)High MRD, ≥ 10−3 (%)P
Total number 246 38 — 
Risk group   Chi-square, < .001 
    Standard risk 160 (65.0) 14 (36.8)  
    High risk 86 (35.0) 24 (63.2)  
WBC count, × 109/L   Chi-square, .02 
    Lower than 50 000 211 (85.8) 27 (71.1)  
    50 000 or higher 35 (14.2) 11 (28.9)  
Age, y   Chi-square, .007 
    0 to younger than 1 7 (2.9) 4 (10.5)  
    1 to younger than 10 205 (83.3) 24 (63.2)  
    10 or older to younger than 18 34 (13.8) 10 (26.3)  
Sex   Chi-square, .61 
    Male 125 (50.8) 21 (55.3)  
    Female 121 (49.2) 17 (44.7)  
Asparaginase treatment   Chi-square, .04 
    Randomized to E coli 82 (33.3) 5 (13.2)  
    Randomized to Erwinia 64 (26.0) 12 (31.6)  
    Direct assigned E coli 100 (40.7) 21 (55.3)  
Relapse   Log rank, < .001 
    Yes 29 (11.8) 27 (71.0)  
    No 217 (88.2) 11 (29.0)  

— indicates not applicable.

or Create an Account

Close Modal
Close Modal